ClinicalTrials.gg

Program

erfonrilimab

Also written as “KN046”, “GT90001+KN046” and “KN046 (PD-L1/CTLA4 BsAb)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Thymoma · Lymphoma · Triple Negative Breast Neoplasms, led by 4 companies.

Furthest: phase 3, since Jul 13, 202014 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology111 open or runningphase 3since Jul 13, 2020May 8, 2018none ahead
Suzhou Kintor Pharmaceutical11 open or runningphase 2since Jul 5, 2021Jul 5, 2021none ahead
Suzhou Zelgen Biopharmaceuticals10 open or runningphase 2since Oct 29, 2020Oct 29, 2020none ahead
Zhejiang Raygene Pharmaceuticals10 open or runningphase 2since Feb 13, 2025Feb 13, 2025none ahead

Also a collaborator on its studies: Sunshine Lake Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2018First study: phase 1 study in Advanced Solid TumorsNew to Alphamab OncologyAlphamab Oncology · NCT03529526 · 21 enrolled · Australia
  2. Oct 31, 2018Phase 1 study in LymphomaAlphamab Oncology · NCT03733951 · 139 enrolled · China
  3. Feb 1, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAlphamab Oncology · NCT03838848 · 120 enrolled · China
  4. Mar 7, 20192 phase 2 studiesAlphamab Oncology · NCT03872791, NCT03925870
  5. Jul 7, 2020Phase 2 study in ThymomaAlphamab Oncology · NCT04469725 · 95 enrolled · China
  6. Jul 13, 2020Phase 3 study in Squamous Non-small-cell Lung CancerAlphamab Oncology · NCT04474119 · 482 enrolled · China
  7. Oct 19, 2020Phase 2 study in Advanced HCCAlphamab Oncology · NCT04601610 · 6 enrolled · China
  8. Oct 29, 2020Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Advanced Gastrointestinal TumorsNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT04612712 · 15 enrolled · China
  9. Jul 5, 2021Suzhou Kintor Pharmaceutical's first study: phase 2 study in Solid TumorNew to Suzhou Kintor PharmaceuticalSuzhou Kintor Pharmaceutical · NCT04984668 · 216 planned · Taiwan
  10. Jul 16, 2021Phase 3 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT05001724 · 16 enrolled · China
  11. Nov 26, 2021Phase 3 study in Advanced Pancreatic Ductal AdenocarcinomaAlphamab Oncology · NCT05149326 · 408 enrolled · China
  12. Jun 12, 2022Phase 2 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT05420220 · 95 enrolled · China
  13. Feb 13, 2025Zhejiang Raygene Pharmaceuticals's first study: phase 2 study in Colorectal NeoplasmsNew to Zhejiang Raygene PharmaceuticalsZhejiang Raygene Pharmaceuticals · NCT06834399 · 42 enrolled · China

TargetBeta

CD274 →CTLA4 →read by rule
“A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06834399Colorectal Neoplasms · China2TerminatedZhejiang Raygene PharmaceuticalsDec 17, 202442
NCT05420220Advanced Non-small Cell Lung Cancer · China2CompletedAlphamab OncologyDec 31, 202495
NCT05149326Advanced Pancreatic Ductal Adenocarcinoma · China3Active, not recruitingAlphamab OncologyApr 30, 2024408
NCT05001724Advanced Non-small Cell Lung Cancer · China3TerminatedAlphamab OncologyFeb 13, 202316
NCT04984668Solid Tumor · Taiwan2RecruitingSuzhou Kintor PharmaceuticalApr 2025216
NCT04612712Advanced Gastrointestinal Tumors · China2TerminatedSuzhou Zelgen BiopharmaceuticalsJun 30, 202215
NCT04601610Advanced HCC · China2TerminatedAlphamab OncologyMay 30, 20226
NCT04474119Squamous Non-small-cell Lung Cancer · China3UNKNOWNAlphamab OncologyAug 30, 2022482
NCT04469725Thymoma · China2TerminatedAlphamab OncologyJul 7, 202395
NCT03925870Esophageal Squamous Cell Carcinoma · China2CompletedAlphamab OncologyAug 26, 202145
NCT03872791Triple Negative Breast Neoplasms · China2CompletedAlphamab OncologyAug 16, 202252
NCT03838848Carcinoma, Non-Small-Cell Lung · China2TerminatedAlphamab OncologyJul 30, 2022120
NCT03733951Lymphoma · China1CompletedAlphamab OncologyJan 3, 2023139
NCT03529526Advanced Solid Tumors · Australia1UNKNOWNAlphamab OncologyOct 30, 201921

How it is read

Names in the registry

  • “KN046”, 11 entries
  • “GT90001+KN046”, 4 entries
  • “KN046 (PD-L1/CTLA4 BsAb)”, 2 entries
  • “KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)”, 1 entry
  • “KN046 Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.